Adempas (Riociguat)

Brand Options

arrow pointer

Brand Name : Adempas

Marketing Authorization Holder : Bayer

Prescription Required


Generic Option

arrow pointer2

Generic Name : Riociguat

Manufactured By : Authorized Indian Generic

Prescription Required


Product Details


Save 85% on brand name Adempas from Europe and over 95% with generic Adempas - all strengths available.

Click here for information on MSN Labs generics (Immediate availability)

For brand Adempas - Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.

According to the European Medicines Agency, brand name Adempas originating from Europe is manufactured at the following site(s):Bayer AG Kaiser-Wilhelm-Allee 51368 Leverkusen Germany

Information about ADEMPAS:

  • Adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4), after surgery are prescribed Adempas (Riociguat) to improve their exercise ability and WHO functional class.
  • Additionally, it is indicated for improving exercise capacity, WHO functional class, and delaying clinical deterioration in adults with pulmonary arterial hypertension (PAH), WHO Group 1, either as monotherapy or in combination with endothelin receptor antagonists or prostanoids.

Product Highlights

  • Studies included patients with WHO functional class II–III.
  • Effective in idiopathic or heritable PAH (61%) and PAH associated with connective tissue diseases (25%).
  • Stimulates soluble guanylate cyclase (sGC) leading to increased levels of cyclic guanosine monophosphate (cGMP), resulting in vasodilation.
  • Requires careful monitoring due to potential for hypotension, particularly in combination with vasodilators.

Key Ingredients

  • Riociguat
  • Cellulose microcrystalline
  • Crospovidone, hypromellose 5cP

Key Benefits

  • Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group 4, after surgical treatment, or inoperable CTEPH.
  • Treatment of adults with pulmonary arterial hypertension (PAH), WHO Group 1.
  • Improves exercise capacity.
  • Improves WHO functional class.
  • Delays clinical worsening in PAH.

Direction For Use

DosageAdministration Schedule
Starting Dose1 mg three times a day
Alternative Starting Dose (if hypotension risk)0.5 mg three times a day
TitrationIncrease by 0.5 mg three times a day, if systolic BP > 95 mmHg and no hypotension symptoms, every 2 weeks
Maximum DoseUp to 2.5 mg three times a day (highest tolerated dosage)
Adjustment for HypotensionDecrease by 0.5 mg three times a day, if hypotension symptoms occur


 colorDebossing Side 2 NDC 50419-xxx-xx 
   Bottle of 9Bottle of 9Bottle of 9
0.5 mgWhite0.5 R250-91250-1250-3
1 mgPale yellow1 R251-91251-1251-3
1.5 mgYellow-orange1.5 R252-91252-1252-3
2 mgPale orange2 R253-91253-1253-3
2.5 mgRed-orange2.5 R254-91254-1254-3

Safety Concern

  • Adempas and all medications should be kept out of children's reach.
  • Adempas should not be used more than 7.5 mg in a single day unless prescribed by a physician.
  • Remind patients that using Adempas in combination with nitrates, nitric oxide donors, or PDE-5 inhibitors is contraindicated.
  • Inform patients of the possible dangers and symptoms of hemoptysis, and urge them to notify their doctors of any suspected symptoms.

Avoid Taking if ADEMPAS:

  • Women who are pregnant or intend to become pregnant should not take Adempas.
  • Not for children.
  • If Medicine is expired.

Image Image Image Image